Your browser doesn't support javascript.
loading
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110ß.
Nakanishi, Yoshito; Walter, Kimberly; Spoerke, Jill M; O'Brien, Carol; Huw, Ling Y; Hampton, Garret M; Lackner, Mark R.
Affiliation
  • Nakanishi Y; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Walter K; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Spoerke JM; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • O'Brien C; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Huw LY; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Hampton GM; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Lackner MR; Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. lackner.mark@gene.com.
Cancer Res ; 76(5): 1193-203, 2016 Mar 01.
Article in En | MEDLINE | ID: mdl-26759240
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Phosphoinositide-3 Kinase Inhibitors / Mutation Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Cancer Res Year: 2016 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Phosphoinositide-3 Kinase Inhibitors / Mutation Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Cancer Res Year: 2016 Document type: Article Country of publication: United States